EpiCypher Launches Fiber-seq, a Breakthrough Multiomic Single-Molecule Genomics Assay

3 September 2025 -- North Carolina, US -- EpiCypher, a pioneer in epigenomic research and technology, announces the launch of CUTANA Fiber-seq, a groundbreaking multiomic genomics platform that captures both genomic and epigenomic information in a single long-read sequencing assay. This first-of-its-kind technology delivers unprecedented resolution of DNA sequence and chromatin features along individual DNA molecules, opening an entirely new dimension of genome biology with wide-ranging applications in basic research, drug discovery, and clinical medicine.

The Fiber-seq workflow begins with nuclei treated with the Hia5 methyltransferase, which deposits 6mA marks at regions of accessible DNA. Chromatin fibers are then extracted and subjected to long-read sequencing (PacBio or Oxford Nanopore Technologies), where both the Hia5-incorporated 6mA modifications and the underlying DNA sequence are directly detected. This generates a single-molecule, multiomic readout that integrates genetic information, endogenous DNA methylation, and chromatin accessibility across long, continuous DNA molecules. Unlike conventional ATAC-seq, Fiber-seq provides base-pair resolution of transcription factor footprints along individual DNA fibers, enabling precise detection of protein–DNA interactions that regulate gene expression.
“Fiber-seq gives an unprecedented view of the genome - not just the sequence, but the epigenomic states of individual DNA molecules,” said Dr. Michael-Christopher Keogh, Chief Scientific Officer at EpiCypher. “This offers a new lens into biology and disease, with transformative implications for fundamental research and translational science.”

As an initial commercial offering, EpiCypher has launched the CUTANA Hia5 for Fiber-seq, the key enzyme used in the optimized Fiber-seq protocol. This enables researchers to rapidly adopt and deploy the platform in their own labs. EpiCypher also now offers Early Access CUTANA Fiber-seq Assay Services, designed to accelerate access to this cutting-edge technology. These services extend the success of EpiCypher’s industry-leading automated CUTANA CUT&RUN platform, offering a powerful suite of tools to study gene regulation at unparalleled resolution.

Fiber-seq technology addresses critical challenges across diverse fields:

• Basic & Translational Research: Map genetic and epigenetic landscapes on individual molecules to uncover complex mechanisms of genome regulation.
• Drug Discovery & Development: Identify and validate novel therapeutic targets by resolving chromatin states and DNA modifications at high resolution.
• Clinical Research & Diagnostics: Enable precision medicine applications, including the diagnosis of rare diseases, as demonstrated in a landmark Nature Genetics publication showcasing Fiber-seq’s power in uncovering genetic drivers of rare disorders.

“We are thrilled to bring epigenomics to the cutting-edge of long read sequencing technology,” added Martis Cowles, Chief Business Officer at EpiCypher. “CUTANA Fiber-seq is the gateway to a powerful new era of single-molecule multiomics that will advance research and precision medicine in ways that were simply not possible using current short read workflows.”

About EpiCypher Inc
EpiCypher was founded in response to the growing demand for high-quality reagents to study chromatin regulation and enable epigenetics-focused drug discovery. The company is at the forefront of chromatin mapping technologies with the CUTANA® platform for ultra-sensitive genomic profiling assays, including CUT&RUN and CUT&Tag, and now, the groundbreaking Fiber-seq platform. EpiCypher also offers the largest collection of defined designer nucleosomes (dNucs) on the market along with complementary high-throughput assays and services. EpiCypher is dedicated to bringing these transformative technologies to market and offers superior products and assay services to researchers worldwide. Visit: www.epicypher.com.